OR WAIT null SECS
Lecanemab and donanemab, monoclonal antibodies for Alzheimer’s, are on the list of drugs in late-stage development that Clarivate analysts will have annual sales of a $1 billion or more in the next five years.
In a new report, analysts at Clarivate, a London-based intelligence and research firm, identified seven experimental treatments in late-stage development that they expect to deliver annual sales of more $1 billion within five years.
They include treatments for common conditions such as Alzheimer’s disease and asthma to those for very rare diseases such as transthyretin amyloidosis, which is characterized by a build-up of deposits of amyloid, a protein, in various organs.Transthyretin amyloidosis is less common among Americans of European descent, where it is estimated to affect one in 100,000 people, but cardiac form affects between 3% and 3.9% of African Americans.
Here are the seven treatments that are likely to achieve blockbuster status in the next five years according to Clarivate: